Vertellus PC Biomaterials Vertellus PC Biomaterials
PC Technology > Clinical Benefits
Vertellus PC Biomaterials - Clinical Benefits


PC Biomaterials offer the following properties:

  • Haemocompatibility

FDA-cleared claim (click for FDA .pdf): "....PC coating aids in the prevention of thrombus formation on the guidewire tip during short-term clinical usage...."

  • Resistant to Bacterial Adhesion and Biofilm Formation

FDA-cleared claim (click for FDA .pdf): "....The coating has been shown to be resistant to staphylococcal biofilm formation and pseudomonal biofilm formation...."

  • Wettable and Dehydration Resistant

FDA-cleared claim (click for FDA .pdf): "....may provide improved comfort for contact lens wearers who experience mild discomfort or symptoms relating to dryness during lens wear...."

The following table summarises how the features of PC materials translate into expected benefits for devices incorporating them:

PC Technology Feature Expected Clinical Benefit
Reduced protein adhesion/activation Increased biocompatibility
Reduced blood activation Reduced risk of thrombus
Reduced bacterial adhesion Reduced risk of infection
Reduced inflammatory response Reduced risk of fibrosis/rejection
Increased patient comfort
Hydrophilic/lubricious coatings Improved comfort, ease of use
Durable Prolonged device effectiveness
Non-toxic and bio-inert Rapid regulatory approval
Drug deliveryStep change in device performance

Many of these benefits have been established in the clinic and there are numerous reports detailing the results from in vitro studies, some of which are shown below. Furthermore, PC polymers have been found to be excellent drug delivery platforms for a broad range of actives. It is widely recognised that drug delivery is proving to be a step-change in the medical device area as passive devices become active devices through release of therapeutic agents such as anti-inflammatories, analgesics, anti-microbials etc. PC Biomaterials offer combined benefits of enhanced biocompatibility with controlled drug-delivery capability.